Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis

Ying Zhang, Xiaou Li, Junhui Liu, Xuereu Hu, Chun Wan, Rui Zhang and Yongchun Shen

ABSTRACT
Objective: This study aimed to assess the diagnostic accuracy of serum LDH to pleural ADA ratio (cancer ratio, CR) for malignant pleural effusion (MPE) through an original study and meta-analysis.

Methods: We retrospectively collected data from 145 patients with MPE and 117 cases of benign pleural effusions (BPE). The diagnostic performance of CR and a typical biomarker of MPE, carcinoembryonic antigen (CEA), were analysed using the receiver operating characteristic (ROC) curves and the area under the curve (AUC) as a measure of accuracy. The overall diagnostic accuracy of CR was summarised by a standard diagnostic meta-analysis.

Results: Significantly higher CR and pleural CEA values were observed in the MPE patients than in the BPE patients. At a cut-off value of 14.97, CR showed high sensitivity (0.91), low specificity (0.67), and high AUC (0.85). The combination of CEA and CR increased the AUC to 0.98. The meta-analysis included seven studies involving 2,078 patients. The pooled values for sensitivity, specificity, positive/negative likelihood ratio, and diagnostic odds ratio of CR were 0.96, 0.88, 7.70, 0.05, and 169, respectively. The AUC of the summary ROC of CR was 0.98.

Conclusion: CR has a high diagnostic accuracy for predicting MPE, especially when used in combination with pleural CEA.

ARTICLE HISTORY
Received 3 December 2020
Revised 5 March 2021
Accepted 17 March 2021

KEYWORDS
Malignant pleural effusion; cancer ratio; carcinoembryonic antigen; diagnosis; meta-analysis

1. Introduction
Malignant pleural effusion (MPE) is a common clinical condition observed in patients suffering from malignant diseases, such as primary thoracic cancer, pleural mesothelioma, metastatic cancer, etc [1–3]. It is associated with unfavourable prognosis and a median survival time of 3–12 months [4–5]. The estimated annual incidence of MPE is between 150,000 and 175,000 in the US [2], and around 40,000 in the UK [3]. MPE is considered to be the first aggressive sign of malignant diseases in approximately 10% of patients [1]. For the purpose of disease staging and the development of effective treatment plans, it is important to diagnose MPE early and accurately by using minimally invasive methods; unfortunately, this continues to be a clinical challenge [6]. A number of tumour markers have been used for the diagnosis of MPE, including vascular endothelial growth factor, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA 15-3, CA 19-9, and CYFRA 21-1 [7–9]. However, none of these markers has shown both high sensitivity and high specificity. Therefore, it is imperative to identify a novel marker to improve the accuracy of MPE diagnoses.

Lactate dehydrogenase (LDH) is a ubiquitous enzyme that occurs in high concentrations in the liver, kidney, myocardium, skeletal muscles, and red blood cells [10]. It plays an important role in glycolysis and gluconeogenesis; an increase in LDH levels can occur as a result of pernicious anaemia, shock, and tumour metastasis [11]. Previous studies have reported that elevated plasma LDH can be used as a diagnostic and prognostic marker to detect sepsis and cancer [12–15]. However, its diagnostic potential as a biomarker for MPE has not been evaluated in detail.

CONTACT Yongchun Shen
shen_yongchun@126.com
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu 610041, China; Rui Zhang
zhangru7@foxmail.com
Department of Medical Informatics, West China Hospital, Chengdu 610041, China

These authors contributed equally to the study.

Supplemental data for this article can be accessed here.

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Adenosine deaminase (ADA) is a known biomarker of benign tuberculous pleural effusion [16,17]. It is secreted by mononuclear cells, lymphocytes, neutrophils, and red blood cells that play an important role in purine nucleoside metabolism [16,17]. Patients with MPE typically show low levels of ADA [16], but whether this can aid MPE diagnosis is unclear. One study reported that patients with MPE had a high serum LDH to pleural ADA ratio (cancer ratio, CR), yield sensitivity and specificity of 0.98 and 0.94 in diagnosing MPE, suggesting that this ratio can be used as a novel marker for MPE [18]. Although several studies have been performed to validate these findings, the results have been inconsistent, so we do not have a clear understanding of the diagnostic performance of the CR for MPE. Here we conducted a retrospective study and meta-analysis of relevant literature to evaluate the diagnostic accuracy of CR as a marker for MPE. We also assessed the potential diagnostic value of CEA, which is a well-known biomarker of MPE.

2. Methods

2.1. Patients

In this retrospective study, we considered 261 consecutive patients suffering from pleural effusion who were admitted to our hospital for further investigation between February 2015 and October 2015. We included all patients who had received a confirmed diagnosis of benign pleural effusion (BPE) or MPE and who had completed routine laboratory tests associated with pleural effusion, as well as tests of serum LDH, pleural ADA, and pleural CEA. Patients with inconclusive final diagnosis and incomplete data were excluded from this study. On admission, all patients signed the informed consent for their anonymized clinical data to be analysed and published for scientific research purposes. This study was approved by the Ethics Committee of our hospital and was conducted based on the principles outlined in the Declaration of Helsinki.

2.2. Diagnostic criteria

In this study, MPE was diagnosed based on the presence of malignant cells in pleural effusion or pleural biopsy specimens [2–3]. In patients with BPE, tuberculous pleural effusion was diagnosed if acid-fast bacteria could be cultured from pleural fluid or sputum, or if granulomas were present in pleural biopsy specimens, or if patients responded well to anti-tuberculosis therapy during follow-up of at least 3 months. Parapneumonic effusion was defined as any effusion associated with bacterial pneumonia, lung abscesses, or bronchiectasis. Two clinicians (YZ and XL) independently evaluated the association between pleural effusion and other comorbidities, such as acute pancreatitis, based on medical history, physical examinations, computed tomography, and patients’ response to treatment.

2.3. Data collection and statistical analysis

We collected data on age, sex, and routine biochemical analysis results on admission, including colour of pleural fluid; levels of pleural glucose, proteins, ADA, and CEA; and serum LDH. Patient demographic data and disease characteristics were summarised and expressed as mean ± standard deviation (mean ± SD). Intergroup differences were assessed for significance using the Mann-Whitney U test. We analysed the receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) to assess the overall diagnostic performance of CR and pleural CEA. The AUCs of different indexes were compared using the nonparametric approach [19]. Further, the cut-off value was selected based on the best diagnostic efficacy having achieved equilibrium between sensitivity and specificity by using Youden’s index. All statistical analyses were performed in SPSS 21.0 (Chicago, IL, USA), all tests were two-sided and differences associated with \( p < .05 \) were considered statistically significant.

2.4. Meta-analysis

We systematically examined the PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure, Wanfang, and Weipu databases to identify studies on MPE published before June 2020. The following search terms were used in each database: “malignant pleural effusion”, “malignant pleural fluid”, “lactate dehydrogenase”, “LDH”, “adenosine deaminase”, “ADA”, “cancer ratio”, “sensitivity”, “specificity”, and “accuracy”. We included original clinical research articles that reported true positive (TP), false positive (FP), false negative (FN), and true negative (TN) data with respect to the use of CR for MPE diagnosis. Only articles published in English and Chinese were considered. Studies were excluded from this meta-analysis for the following reasons: (1) there were on data of sensitivity and specificity; (2) they were not based on human subjects; (3) Conference proceedings and studies published only as abstracts.
All records were imported into Endnote for further review. Two reviewers (YZ and XL) independently evaluated the studies initially based on titles and abstracts and subsequently based on full text. After removing inappropriate and duplicate studies, the reviewers assessed the quality of the included studies using a revised version of QUADAS-2 [20].

The indices of test accuracy, sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR), along with 95% confidence intervals (CIs), were pooled from each study using a bivariate model. Heterogeneity among all eligible studies was evaluated based on $I^2$: an $I^2 > 50\%$ indicated significant heterogeneity. The diagnostic performance of CR and CEA was assessed based on the summary ROC (SROC) curve. Potential publication bias was evaluated by using Deeks’ test [21]. Meta-analysis was performed in Stata 15.0 (Stata Corp, College Station, TX, USA), and $p < .05$ indicated statistical significance.

3. Results

3.1. Patient characteristics

We collected data on the clinicopathological characteristics of a total of 145 patients diagnosed with MPE and 117 patients diagnosed with BPE (Table 1). The selection process was outlined in Supplementary Figure 1. We found that a large proportion of patients with MPE suffered from lung cancer ($n = 121$), metastatic cancer ($n = 8$), and pleural mesothelioma ($n = 3$). A large proportion of the BPE patients suffered from tuberculous pleural effusion ($n = 68$), followed by parapneumonic effusion ($n = 44$), hepatic pleural effusion ($n = 2$), pleural effusion due to acute pancreatitis ($n = 2$), and chylothorax ($n = 1$).

3.2. Serum LDH and pleural ADA levels

Patients with MPE had significantly higher levels of serum LDH than those with BPE (215.77 ± 101.95 U/l vs 174.44 ± 49.03 U/l; $p < .001$). Conversely, pleural ADA levels were significantly higher in patients with BPE than those with MPE (19.21 ± 27.59 U/l vs 8.00 ± 3.77 U/l; $p < .001$). Therefore, CR levels were significantly higher in MPE patients (32.96 ± 25.31) than in BPE patients (14.50 ± 9.37; $p < .001$).

3.3. Diagnostic performance of CR and pleural CEA

ROC curves were created to summarise and compare the diagnostic performance of CR and pleural CEA as markers for MPE (Figure 1). At a cut-off value of 14.97, CR had an AUC value of 0.852. As the cut-off value raised, the specificity of the rule increased, whereas the sensitivity concurrently decreased (Supplementary Table 1). With the maximisation value of the Youden index, the best cut-off was 15, along with a sensitivity value of 0.91 and a specificity value of 0.67. On the other hand, CEA had an AUC of 0.91 at a cut-off value of 2.57 ng/ml, along with a sensitivity value of 0.81 and a specificity value of 0.94. A combination of the two markers increased the sensitivity (0.93), specificity (0.92), and AUC values (0.98), which was significantly higher than CR alone ($p < .05$).

3.4. Meta-analysis

We performed a meta-analysis of 7 studies (including the present one) involving 860 patients with MPE and 1,218 patients with BPE [18,22–26]. These studies were published from 2016 to present, across five countries, three in China, two in Singapore, one in Egypt, and one in Poland. Figure 2 outlines the process of selecting studies. The clinical characteristics of the patients are listed in Table 2.

Quality assessment of eligible studies is shown in Figure 3. We observed a patient selection bias in four studies: three studies (including the present one) [18,25] used a retrospective approach and one study enrolled only patients with lymphocytic predominant exudative pleural effusion [22]. For reference standard, all the studies reported the methods to diagnose MPE including cytology and biopsy. Risk of bias related to

---

**Table 1.** Characteristics of the patients with pleural effusions in the present clinical study.

| MPE | BPE | $p$ value |
|-----|-----|-----------|
| Number of patients | 145 | 117 | .001 |
| Age (year) | 61.47 ± 13.09 | 54.17 ± 18.67 | .001 |
| Gender | | | .054 |
| Male | 81 | 79 | .054 |
| Female | 64 | 38 | |
| Colour of pleural effusion | | | .001 |
| Yellow | 81 | 76 | |
| Red | 53 | 19 | .001 |
| Yellow-red | 11 | 19 | .001 |
| Purulent/Chylous | 0 | 3 | .001 |

| Laboratory result | | | |
|-------------------|-----------------|-----------------|-----------------|
| Serum LDH (U/l) | 215.77 ± 101.95 | 174.44 ± 49.03 | <.001 |
| Pleural glucose (U/l) | 6.11 ± 2.39 | 5.50 ± 2.78 | .009 |
| Pleural protein (g/l) | 41.33 ± 10.17 | 45.51 ± 8.13 | <.001 |
| Pleural ADA (ng/ml) | 186.90 ± 271.77 | 1.34 ± 2.54 | <.001 |
| Pleural CEA (ng/ml) | 8.00 ± 3.77 | 257.59 ± 15.37 | <.001 |

BPE: Benign pleural effusion; MPE: Malignant pleural effusion; CEA: carcino-embryonic antigen; LDH: lactate dehydrogenase; Cancer ratio: serum LDH / pleural ADA.
the follow-up and timing domains were high in one study [18] because patients without a final diagnosis were excluded from analysis.

To evaluate the diagnostic accuracy of CR with respect to MPE, we calculated pooled values of sensitivity (0.96, 95% CI 0.93–0.98; Figure 4(a)), specificity

**Figure 1.** Receiver operating characteristic curves showing the performance of the cancer ratio and levels of carcinoembryonic antigen for diagnosing MPE.

**Figure 2.** Flow diagram of study selection in the meta-analysis.
(0.88, 95% CI 0.73–0.95; Figure 4(b)), PLR (7.7, 95% CI 3.3–8.8), NLR (0.05, 95% CI 0.02–0.09), and DOR (169, 95% CI 39–726). The SROC curve also shows that the AUC is 0.98 (95% CI 0.96–0.99; Figure 5). These values indicate that CR is valuable for diagnosing MPE.

Our evaluation of the included studies suggests that there was significant heterogeneity with respect to the sensitivity (I² = 81.17%) and specificity (I² = 96.83%) (p < .05). However, we could not perform a meta-regression analysis to investigate the source of heterogeneity due to the limited number of included studies. We found no significant evidence of publication bias based on the Deek’s funnel plot (p = .22; Figure 6).

4. Discussion
There is a critical need to identify a simple and effective biomarker for MPE. Studies have reported an increase in the CR in patients with MPE, suggesting that CR can be used as a novel diagnostic marker for MPE. Our study aimed to validate the diagnostic performance of CR using retrospective data collected from a Chinese cohort as well as meta-analysis of the
Our results show that CR can be used as an effective marker for the diagnosis of MPE, especially in combination with CEA.

CR was first proposed as a predictor of MPE in 2016, when this ratio was found to be significantly higher in patients with MPE compared to those with tuberculous pleural effusion or parapneumonic effusion [18]: this study reported a cut-off level > 20 for CR, along with high sensitivity (0.98, 95% CI 0.92–0.99) and specificity (0.94, 95% CI 0.83–0.98). Our validation study of 262 patients with pleural effusion also found high sensitivity (0.91) and AUC (0.85), confirming the diagnostic accuracy of CR. However, the low specificity (0.67) indicates that although CR can be a sensitive biomarker of MPE, diagnoses based on this biomarker should be confirmed using other methods. We noticed the specificity of our study is lower than previous study [18,22], it may be caused by the different percentage of patients with MPE, aetiology of MPE, the previous studies enrolled more patients with lung cancer (95% and 97.6%) [18,22], while in our study, the

Figure 4. Forest plots of (a) sensitivity and (b) specificity of the cancer ratio for diagnosing MPE, along with 95% confidence intervals (CIs).

Figure 5. Summary receiver operating characteristic curve assessing the performance of the cancer ratio for diagnosing MPE.
percentage of lung cancer in MPE was only 83%. Since the levels of LDH may be associated with different types of tumour, thus, the clinical interpretation of CR results should consider these issues.

The results of our meta-analysis of the diagnostic performance of CR also showed high pooled values of sensitivity (0.96) and specificity (0.88). The SROC curve, which assesses overall test performance and depicts the trade-off between sensitivity and specificity, gave an AUC of 0.98, indicating a high overall accuracy. The DOR value combines sensitivity and specificity data into a single number ranging from 0 to infinity; higher DOR values indicate better discriminatory test performance [27]. The mean DOR in our meta-analysis was 169, suggesting that it is useful to consider CR levels during the diagnosis of MPE. Similarly, the pooled PLR value (7.7) suggests that MPE patients are approximately seven times more likely to have a positive CR assay result than BPE patients. The pooled NLR value (0.05) indicates a 5% likelihood that a patient whose CR is too low to qualify as MPE actually does have MPE. In fact, Han et al. also summarised the overall diagnostic performance of CR for MPE, and they only included five studies [28]. In our study, first, we performed our retrospective study to validate the previous findings; second, we enrolled more studies (total seven studies) to make a more objective conclusion. Third, we performed publication bias examination. Our study provided more evidence regarding on CR in the diagnosis of MPE.

There are several advantages with respect to the clinical utility of CR for the diagnosis of MPE. First, nearly all patients with undiagnosed pleural effusion undergo routine blood and pleural biochemical tests. Therefore, it is easy to obtain data on LDH and ADA levels, without incurring any additional costs. Second, this data can help guide treatment plans: patients with high CR values must be treated with caution, and further diagnostic examinations such as repeated cytologic test, invasive procedures such as medical thoracoscopy and pleural biopsy should be considered. While, the best cut-off value of CR has not been established, a presepcified threshold value is needed since a data-driven threshold may overstate an index test [29].

CEA has been widely used in the diagnosis of MPE. A meta-analysis based on 45 studies showed low pooled sensitivity (0.54) and high pooled specificity
(0.94) for CEA when diagnosing MPE, the low sensitivity of CEA limited its role in screening MPE [7]. The present study also showed that pleural CEA is a valuable biomarker for MPE (AUC 0.91), which is higher than CR. Recent studies also identified that pleural/serum CEA ratio is also helpful for diagnosing MPE, at a cut-off value of 1, the sensitivity and specificity of CEA ratio for diagnosing MPE were 85% and 92%, respectively [30,31], and supplied additional clue for MPE. The diagnostic sensitivity of CEA is moderate, therefore, in clinical practice, the results of CEA assays should be interpreted together with clinical findings and conventional laboratory tests. In fact, the combination of CR and CEA led to higher diagnostic accuracy (AUC 0.98) than either biomarker on its own. Thus, we propose that clinicians combine CR and CEA to arrive at an accurate MPE diagnosis.

The results of our study must be interpreted with caution in the light of several limitations. Due to the retrospective nature of our study, we were unable to obtain all the relevant data required for our analysis from the hospital’s medical records, and we didn’t calculate the sample size and also can’t calculate the diagnostic performance of CEA ratio for MPE. Additionally, most of the included studies used patients with tuberculous pleural effusion and parapneumonic effusion as controls. Other aetiologies of pleural effusion, such as heart failure, chemical pleurisy, or connective tissue disease were not included. In order to extend our results, future work must include clinical data from a larger cohort of patients with many different types of pleural effusion. The limited number of studies included in our meta-analysis was also another source of bias, especially since we could not evaluate covariates as possible sources of the observed heterogeneity [32].

5. Conclusion

In summary, our study and meta-analysis demonstrate that CR is an effective diagnostic marker for MPE, especially in combination with CEA. Further research is required to validate these findings.

Ethical approval

Written informed consent was collected from all patients. This study was approved by the Ethics Committee of West China Hospital of Sichuan University (2020-147) and was conducted based on the principles outlined in the Declaration of Helsinki.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This study was supported by the 1:3:5 Project for Disciplines of Excellence at West China Hospital of Sichuan University [2019HXFH042] and by the Sichuan Key Research and Development Program [2020YS0147]. These funding agencies were not involved in designing the study, collecting or analysing the data, writing the manuscript, or making decisions related to publication.

Data availability statement

All data used to support the findings of the current study are available from the corresponding authors upon reasonable request.

References

[1] Meriggi F. Malignant pleural effusion: still a long way to go. Rev Recent Clin Trials. 2019; 14(1):24–30.
[2] Thomas JM, Musani Al. Malignant pleural effusions: a review. Clin Chest Med. 2013;34(3):459–471.
[3] Egan AM, McPhillips D, Sarkar S, et al. Malignant pleural effusion. QJM. 2014;107(3):179–184.
[4] Montero-Arias F, Cartín-Ceba R, Rojas-Solano J, et al. Pleural effusion size as prognostic marker in patients with malignant pleural effusion. Pleura. 2015;2:237399751560065.
[5] Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014; 69(12):1098–1104.
[6] Zhu J, Feng M, Liang L, et al. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis. BMC Cancer. 2017;17(1):590.
[7] Shi HZ, Liang QL, Jiang J, et al. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respiratory. 2008;13(4):518–527.
[8] Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63(1):35–41.
[9] Shen YC, Liu MQ, Wan C, et al. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: a meta-analysis. Exp Ther Med. 2012;3(6):1072–1076.
[10] Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292(5516):504–507.
[11] Lott JA, Nemensanszky E. Lactate dehydrogenase. In: Lott JA, Wolf PL (eds) Clinical enzymology, a case oriented approach. New York: Year Book Medical; 1987. pp 213–244.
[12] Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425–434.

[13] Lv J, Zhou Z, Wang J, et al. Prognostic value of lactate dehydrogenase expression in different cancers: a meta-analysis. Am J Med Sci. 2019; 358(6):412–421.

[14] Feng Y, Xiong Y, Qiao T, et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2015;113(9):1389–1396.

[15] Porcel JM, Esquerda A, Bielsa S. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med. 2010;21(5):419–423.

[16] Verma A, Dagaonkar RS, Marshall D, et al. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (Cancer Ratio: Pleural Lymphocyte Count). Can Respir J. 2016;2016:7348239

[17] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.

[18] Verma A, Dagaonkar RS, Marshall D, et al. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (Cancer Ratio: Pleural Lymphocyte Count). Can Respir J. 2016;2016:7348239

[19] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.

[20] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.

[21] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.

[22] Verma A, Dagaonkar RS, Marshall D, et al. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (Cancer Ratio: Pleural Lymphocyte Count). Can Respir J. 2016;2016:7348239

[23] Zhang F, Hu L, Wang J, et al. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. J Clin Lab Anal. 2017;31(5):e22106.

[24] Elmahalawy II, Abdelaal GA, Alhanafy AM, et al. Role of cancer ratio and carcinogenic embryonic antigen ratio in diagnosis of pleural effusion. Egypt J Chest Dis Tuberc. 2017;66(4):671–674.

[25] Korczyński P, Mierzejewski M, Krenke R, et al. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions. Pol Arch Intern Med. 2018;128(6):354–361.

[26] Jiang L, Zhou Q, He L, et al. Diagnostic value of plasma LDH/ADA rational pleural effusion in malignant pleural effusion. Med J West China. 2018; 30(1):31–34.

[27] Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–1135.

[28] Han YQ, Zhang L, Yan L, et al. Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis. J Clin Transl Med. 2019;7(2):554.

[29] Leeflang MM, Moons KG, Reitsma JB, et al. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem. 2008;54(4):729–737.

[30] Hackner K, Erhardt P, Handschuh S. Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion. Ther Adv Med Oncol. 2019;11:1758835919850341

[31] Zhai K, Wang W, Wang Y, et al. Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study. J Thorac Dis. 2017;9(12):5220–5229.

[32] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.